Yair Gazitt, Ph.D.
Associate Professor, Department of Medicine
Director of the Bone Marrow Transplant Lab
Division of Hematology
|
Location: |
DTL, Room 5.011R |
|
E-mail: |
Research Interests:
Mode of action of gemcitabine and taxol. Mechanism of drug resistance in multiple myeloma. Involvement of bcl2 family of proteins and p53 in apoptosis in multiple myeloma.
Unique Technical and Clinical Research Capabilities/Instrumentation:
Hematopoietic stem cell manipulations; flow-sorting; determination of minimal residual disease bv CDRIII-based PCR.
Publications:
Gazitt Y., Tian E., Barlogie B., Reading C.L., Vesole D., Jagannath S., Schnell J., Hoffman R, and Tricot G. Differential Peripheral blood mobilization of tumor and normal hematopoietic progenitor cells in multiple myeloma. Blood 87:805-811, 1996.
Tian E. and Gazitt Y. The role of bcl-2, bax and P53 oncogenes in dexamethoasone induced apoptosis in human multiple mycloma cell lines. Int. J. Oncol. 8:719-726, 1996.
Hu W-X. and Gazitt Y. Bcl-2 plays a major role in resistance to apoptosis in myeloma cells. Int. J. Oncol. 9:375-382, 1996.
Tian E., Hu W-X. and Gazitt Y. Bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in multiple myeloma cell lines: A studv with inducible bcl-2 transfection constructs. Int. J. Oncol. 9:165-169, 1996.
Reading C.L., Juttner C., Gazitt Y. and Estrov Z. Does CD34+ cell selection enrich for malignant stem cells in B-cell (and other) malignancies? J. Hematolother. 5:97-98, 1996.
Jethamalani S.M., Henle K.J., Gazitt Y., Walker P.D., Wang S.H. Intracellular distribution of heat-induced stress glycoproteins. J. Cell. Biochem. 66:98, 111, 1997.
Stone F.J., Morgan R., Chen Z., Sandberg A.A. and Gazitt Y. Use of a medium conditioned by the AGF cell line for bone marrow cytogenetic preparations. Cancer Genetics Cytogen. 1997, in press.
Gazitt Y. and Hilsenbeck S.G. Pitfalls in the RNA-based amplification of the CDRIII sequence for quantitation of minimal residual disease. Oncol. Reports 4:1387-1390, 1997.
Gazitt Y. and Hu W-X. Fas (APO-1/CD95)-mediated apoptosis is independent of bcl-2: A study with cell lines overexpressing bcl-2 and with bcl-2 transfected cell lines. Int. J. Oncol. 12:211-220, 1998.
Tricot G., Gazitt Y., Leemhuis T., Jagannath S., Desikan KR., Siegel D., Fassas A., Tindel S., Nelson J., Juttner C., Tsukamoto A., Hallagan J., Atkinson K., Hoffman R., and Barlogie B. Collection, engraftment kinetics and tumor contamination of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood, 91:4489-4495, 1998.
Gazitt Y. Rothenberg ML., Hilsenbeck S. L., Fey V., Thomas C., and Montgomery W. Bcl-2 overexpression is associated with resistance to paclitaxel but not gemcitabine in multiple myeloma cell lines. Int. J. Oncol. 13:839-848, 1998.
Gazitt Y., Fey V., Thomas C. and Alvarez R. Bcl-2 overexpression is associated with resistance to dexamethasone but not melphalan in multiple myeloma cell lines. Int. J. Oncol. 13:397-405, 1998.
Key Words:
myeloma; drug resistance; bcl family of proteins; stem cell; apoptosis